Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573543 | 1.00 | TSHR (0.48) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL26636753 | 0.83 | TSHR (0.46) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL29654850 | 0.81 | — | — | |
| SCHEMBL24227 | 0.81 | — | — | |
| SCHEMBL13608129 | 0.81 | — | — | |
| SCHEMBL23249686 | 0.81 | — | — | |
| SCHEMBL8827532 | 0.81 | TSHR (0.39) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL12649841 | 0.79 | TSHR (0.42) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10239103 | 0.78 | TSHR (0.65) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL17751390 | 0.78 | TSHR (0.65) | TSHRTDP1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEAGEN INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3513794-A2 | FUCOSE ANALOGS FOR INHIBITION OF PROTEIN FUCOSYLATION IN VIVO | Seattle Genetics, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEATTLE GENETICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2608796-B1 | INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9504702-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEATTLE GENETICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2608796-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | Seattle Genetics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019165-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.